{"disease":{"id":"triple-negative-breast-cancer-tnbc","name":"triple negative breast cancer tnbc"},"drugs":{"marketed":[{"drug_id":"immuno-oncology-io","indication_name":"Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"immuno-oncology-io","indication_name":"Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"pf-06865571","indication_name":"Triple-Negative Breast Cancer (TNBC) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Triple-Negative Breast Cancer (TNBC) in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":26,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06606730","title":"Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2454,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT07407517","title":"Adjuvant Intensification for LAR","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":904,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT02819518","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":882,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07246759","title":"Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"OncoHost Ltd.","has_results":false},{"nct_id":"NCT06476119","title":"OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes","phase":"","overall_status":"RECRUITING","enrollment_count":490,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT02178722","title":"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06885424","title":"A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT06545331","title":"Study of XB010 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06831955","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":356,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT06682793","title":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT07498400","title":"Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":216,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT07029399","title":"A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":205,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07073755","title":"Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT06768931","title":"Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":192,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07487519","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT07182149","title":"A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Normunity AccelCo, Inc.","has_results":false},{"nct_id":"NCT07218003","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":149,"lead_sponsor_name":"Rondo Therapeutics","has_results":false},{"nct_id":"NCT01884285","title":"AZD8186 First Time In Patient Ascending Dose Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03549000","title":"A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05827614","title":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Boundless Bio, Inc.","has_results":false},{"nct_id":"NCT07069595","title":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03746431","title":"A Phase 1 Study of [225Ac]-FPI-1434 Injection","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Fusion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03742349","title":"Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":64,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05555706","title":"Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","has_results":false},{"nct_id":"NCT07509515","title":"QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07486089","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT06975644","title":"Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false},{"nct_id":"NCT03057600","title":"Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":true},{"nct_id":"NCT02435680","title":"Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05383196","title":"Onvansertib + Paclitaxel In TNBC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Antonio Giordano, MD","has_results":false},{"nct_id":"NCT04424641","title":"A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":48,"lead_sponsor_name":"Genmab","has_results":true},{"nct_id":"NCT07153965","title":"Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":47,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07005583","title":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07208149","title":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Shenzhen Majory Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07484776","title":"Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Universidad Europea de Madrid","has_results":false},{"nct_id":"NCT06189209","title":"Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Rhizen Pharmaceuticals SA","has_results":false},{"nct_id":"NCT06793332","title":"BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06910072","title":"Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07342283","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Affiliated Hospital of Nantong University","has_results":false},{"nct_id":"NCT03855358","title":"A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05949021","title":"OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Mridula George, MD","has_results":false},{"nct_id":"NCT06220214","title":"Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Alison Stopeck","has_results":false},{"nct_id":"NCT05088057","title":"Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Aiping Shi","has_results":false},{"nct_id":"NCT07441512","title":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":26,"lead_sponsor_name":"Hu Hai","has_results":false},{"nct_id":"NCT06586866","title":"JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"JenKem Technology Co., Ltd.","has_results":false},{"nct_id":"NCT07187674","title":"The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Harbin Medical University","has_results":false},{"nct_id":"NCT06880029","title":"Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}